U.S. FDA Sees Progress Working Within China, And More Help Is On The Way
This article was originally published in PharmAsia News
Executive Summary
FDA hopes an expanded staff in China will help overcome new hurdles as the agency learns more about the country's manufacturing and quality system processes.
You may also be interested in...
Love From Shanghai: Upjohn Started Here But Will It Stay Post-Mylan?
Opened with a big splash just two months ago in a brand new headquarters in Shanghai, Pfizer's Upjohn established products subsidiary is now merging with Mylan to create the world's largest generics group, stirring up local concerns that the focus could shift from China back to the US.
China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 2 of 2)
U.S.FDA established offices in China in 2008 to improve oversight of products exported to the U.S., and to establish stronger working relationships with China's State FDA. The mission of the office initially was to implement two export agreements signed with China in December 2007 to enhance regulatory cooperation in the areas of food, drugs, medical devices and animal feed. PharmAsia News' China and Australia bureaus spoke to FDA China Country Director Christopher Hickey about the mission of the China office and progress being made in China. This is part two of a two-part interview; part one appeared in a recent issue of PharmAsia News.